| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
29,335 |
25,952 |
$1.70M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,938 |
5,268 |
$1.48M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
22,852 |
20,061 |
$745K |
| 80053 |
Comprehensive metabolic panel |
20,598 |
18,110 |
$186K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,603 |
2,349 |
$98K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
629 |
618 |
$80K |
| 85027 |
|
18,642 |
16,535 |
$67K |
| 86710 |
|
4,929 |
4,352 |
$66K |
| 71045 |
Radiologic examination, chest; single view |
10,184 |
9,149 |
$48K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,763 |
4,067 |
$44K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,243 |
3,731 |
$42K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,971 |
2,614 |
$40K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,596 |
1,489 |
$33K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,732 |
3,020 |
$31K |
| 81003 |
|
11,481 |
9,928 |
$27K |
| 70450 |
Computed tomography, head or brain; without contrast material |
330 |
295 |
$23K |
| 80081 |
|
344 |
295 |
$20K |
| G0378 |
Hospital observation service, per hour |
504 |
335 |
$19K |
| D9420 |
|
75 |
69 |
$19K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
142 |
82 |
$17K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
6,885 |
3,670 |
$16K |
| 71046 |
Radiologic examination, chest; 2 views |
1,565 |
1,367 |
$14K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
107 |
99 |
$13K |
| 83690 |
|
2,153 |
1,880 |
$12K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
30 |
28 |
$12K |
| 81001 |
|
3,634 |
2,980 |
$12K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
55 |
53 |
$12K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
260 |
238 |
$11K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,664 |
4,134 |
$9K |
| 84703 |
|
1,616 |
1,424 |
$8K |
| 87807 |
|
689 |
629 |
$7K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
303 |
258 |
$6K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
294 |
257 |
$5K |
| 87070 |
|
457 |
363 |
$5K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
42 |
24 |
$4K |
| 86787 |
|
258 |
232 |
$4K |
| 83605 |
|
445 |
405 |
$4K |
| 86803 |
|
252 |
215 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
260 |
232 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
265 |
250 |
$4K |
| 84484 |
|
567 |
485 |
$4K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
97 |
76 |
$4K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
49 |
26 |
$3K |
| 81025 |
|
871 |
642 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
242 |
216 |
$2K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
33 |
28 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
378 |
323 |
$2K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
56 |
12 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
146 |
112 |
$1K |
| 83735 |
|
199 |
163 |
$1K |
| 80055 |
|
19 |
15 |
$1K |
| 82553 |
|
136 |
106 |
$977.00 |
| 82550 |
|
201 |
159 |
$975.56 |
| 87040 |
|
84 |
81 |
$921.30 |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
28 |
25 |
$902.29 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13 |
12 |
$878.76 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,241 |
2,842 |
$830.68 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
63 |
42 |
$619.84 |
| 86780 |
|
31 |
30 |
$615.84 |
| 74018 |
|
72 |
51 |
$535.26 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
933 |
817 |
$515.03 |
| 85610 |
|
108 |
99 |
$510.54 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
327 |
292 |
$452.23 |
| 85014 |
|
179 |
157 |
$447.63 |
| 80061 |
Lipid panel |
30 |
27 |
$436.25 |
| 83525 |
|
46 |
43 |
$404.40 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,571 |
3,179 |
$381.88 |
| 59025 |
Fetal non-stress test |
63 |
46 |
$368.16 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
16 |
15 |
$367.51 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
888 |
698 |
$356.77 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
743 |
637 |
$349.26 |
| 86765 |
|
30 |
12 |
$300.84 |
| 86592 |
|
64 |
60 |
$290.88 |
| 87081 |
|
41 |
25 |
$267.00 |
| 80076 |
|
43 |
39 |
$264.96 |
| 85730 |
|
91 |
86 |
$227.15 |
| 82607 |
|
12 |
12 |
$226.08 |
| 82105 |
|
12 |
12 |
$225.10 |
| 82950 |
|
30 |
28 |
$197.96 |
| J1790 |
Injection, droperidol, up to 5 mg |
68 |
58 |
$192.96 |
| 85379 |
|
18 |
16 |
$192.66 |
| 82803 |
|
13 |
13 |
$171.18 |
| 86850 |
|
25 |
25 |
$167.58 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,903 |
3,459 |
$167.20 |
| 87186 |
|
13 |
12 |
$120.15 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
12 |
12 |
$107.76 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
81 |
63 |
$76.12 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
14 |
12 |
$67.20 |
| 86140 |
|
29 |
13 |
$26.37 |
| 86900 |
|
12 |
12 |
$26.04 |
| 86901 |
|
12 |
12 |
$25.80 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
125 |
119 |
$1.04 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
15 |
15 |
$0.00 |
| 88312 |
|
47 |
43 |
$0.00 |
| 0353U |
|
13 |
12 |
$0.00 |
| 0240U |
|
554 |
528 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
364 |
339 |
$0.00 |
| A9270 |
Non-covered item or service |
5,149 |
3,684 |
$0.00 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
813 |
727 |
$0.00 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
160 |
150 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
26 |
25 |
$0.00 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
42 |
39 |
$0.00 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
26 |
26 |
$0.00 |